NEO - ネオス・ファ―マシュ―ティカルズ (NeoGenomics Inc.)

NEOのニュース

   NeoGenomics – Consensus Indicates Potential 87.7% Upside  2022/05/06 11:29:26 DirectorsTalk
NeoGenomics found using ticker (NEO) have now 11 analysts in total covering the stock. The consensus rating is ''Buy''. The range between the high target price and low target price is between 26 and 12 with a mean TP of 19.09. With the stocks previous close at 10.17 this would indicate that there is a potential upside of 87.7%. The day 50 moving average is 14.83 and the 200 moving average now moves to 32.33. The company has a market capitalisation of $1,227m. Company Website: https://www.neogenomics.com [stock_market_widget type="chart" template="basic" color="green" assets="NEO" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $2,304m based on the market concensus. NeoGenomics operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers.
   NeoGenomics To Participate in the BofA Securities 2022 Healthcare Conference  2022/05/05 20:05:00 Wallstreet:Online
FT MYERS, FL / ACCESSWIRE / May 5, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that senior management will be participating in …
   Cybin Announces CYB003 Poster to be Presented at the ‘From Research to Reality’ Global Summit on Psychedelic-Assisted Therapies and Medicine  2022/05/05 12:00:00 Kwhen Finance
   NeoGenomics, Biognosys Partner to Flesh Out Proteomics Offerings for Pharma Market  2022/04/28 17:29:45 GenomeWeb
At the core of the relationship is the combination of Biognosys'' mass spectrometry-based proteomics workflows and NeoGenomics'' spatial proteomics platform.
   NeoGenomics Inc.''s (NEO) Q1 2022 Results - Earnings Call Transcript  2022/04/27 18:58:14 Seeking Alpha
NeoGenomics, Inc. (NASDAQ:NASDAQ:NEO) Q1 2022 Earnings Conference Call April 27, 2022, 08:30 AM ET Company Participants Lynn Tetrault - Executive Chair & Principal Executive Officer…
   Kontrol Technologies Files Revised Business Acquisition Report and Provides Update on Proposed US Listing Application  2022/04/14 21:00:00 Kwhen Finance
   Nextech AR Launches Shopify Freemium 3D Model Pricing  2022/04/12 11:30:00 Kwhen Finance
   Greenland Resources Announces Filing of the Ni 43-101 Feasibility Study on the Malmbjerg Molybdenum Project  2022/04/12 02:08:00 Kwhen Finance
   NeoGenomics Announces That Inivata Liquid Biopsy Subsidiary and Collaborators Have Published Clinical Validation Data for RaDaR(TM) Assay MRD Assay at AACR 2022  2022/04/11 14:00:00 Wallstreet:Online
Data demonstrates potential of RaDaR to predict clinical response in stage III urothelial cancerFT. MYERS, FL / ACCESSWIRE / April 11, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global …
   NeoGenomics, Inc. Expands Its Global Strategic Partnership Initiatives with Biognosys AG on Multiple Next Generation Proteomics Solutions Supporting Biopharma R&D  2022/04/11 11:00:00 Wallstreet:Online
NeoGenomics continues to add to its state-of-the-art multiomics solutions in world-class biopharma clinical trial and research services for global pharma companiesFORT MYERS, FL / ACCESSWIRE / April 11, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a …
   Nextech AR Signs 3D Model Deal With Major B2B Design Industry Technology Platform and Marketplace DesignerInc  2022/02/01 12:30:00 Kwhen Finance
   Neogenomics Inc. Shares Fall 1.3% Below Previous 52-Week Low - Market Mover  2022/01/28 09:04:48 Kwhen Finance
Neogenomics Inc. (NEO) shares closed 1.3% lower than its previous 52 week low, giving the company a market cap of $2B. The stock is currently down 37.3% year-to-date, down 61.0% over the past 12 months, and up 155.1% over the past five years. This week, the Dow Jones Industrial Average fell 2.5%, and the S&P 500 fell 4.1%. Trading Activity Trading volume this week was 3.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 400.4% The company's stock price performance over the past 12 months lags the peer average by -800.6% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 345.2% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Neogenomics Inc. Shares Near 52-Week Low - Market Mover  2022/01/14 12:46:25 Kwhen Finance
Neogenomics Inc. (NEO) shares closed today at 0.6% above its 52 week low of $24.85, giving the company a market cap of $3B. The stock is currently down 26.8% year-to-date, down 52.7% over the past 12 months, and up 190.6% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 0.7%. Trading Activity Trading volume this week was 28.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 453.2% The company's stock price performance over the past 12 months lags the peer average by -373.2% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 391.9% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Scotia Global Asset Management Returns to NEO Exchange With Launch of 4 Socially Responsible Investing ETFs  2022/01/13 14:21:00 Kwhen Finance
   NEO Exchange Announces Breakthrough Listing in Food Sector With IPO of Plantable Health  2022/01/12 13:00:00 Kwhen Finance

calendar